Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Albireo Pharma Inc (ALBO)

Albireo Pharma Inc (ALBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 591,206
  • Shares Outstanding, K 19,195
  • Annual Sales, $ 8,310 K
  • Annual Income, $ -107,630 K
  • 60-Month Beta 1.55
  • Price/Sales 73.36
  • Price/Cash Flow N/A
  • Price/Book 4.12
Trade ALBO with:

Options Overview

Details
  • Implied Volatility 68.66%
  • Historical Volatility 54.05%
  • IV Percentile 13%
  • IV Rank 5.17%
  • IV High 282.75% on 08/21/20
  • IV Low 56.98% on 01/15/21
  • Put/Call Vol Ratio 0.48
  • Today's Volume 525
  • Volume Avg (30-Day) 898
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 8,783
  • Open Int (30-Day) 5,341

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -1.92
  • Number of Estimates 6
  • High Estimate -1.56
  • Low Estimate -2.24
  • Prior Year -1.38
  • Growth Rate Est. (year over year) -39.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.37 +1.42%
on 07/23/21
37.86 -18.65%
on 07/20/21
-4.73 (-13.31%)
since 06/23/21
3-Month
27.53 +11.86%
on 05/11/21
37.86 -18.65%
on 07/20/21
-0.56 (-1.79%)
since 04/23/21
52-Week
22.78 +35.21%
on 08/13/20
49.00 -37.14%
on 09/08/20
+4.54 (+17.29%)
since 07/23/20

Most Recent Stories

More News
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

BMRN : 77.04 (-1.81%)
EXAS : 117.95 (-0.07%)
ALBO : 30.80 (-2.99%)
TVTX : 13.23 (+1.93%)
MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay(TM) (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

- Only once-daily drug indicated for the treatment of pruritus in PFIC -

ALBO : 30.80 (-2.99%)
Albireo Announces FDA Approval of Bylvay(TM) (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

- Only once-daily drug indicated for the treatment of pruritus in PFIC -

ALBO : 30.80 (-2.99%)
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval

Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.

CDXS : 20.95 (-1.23%)
ALBO : 30.80 (-2.99%)
BCYC : 35.31 (+1.15%)
ARQT : 24.38 (-2.28%)
Albireo Receives European Marketing Authorization of Bylvay(TM) (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)

- First approval in the world of Bylvay for the treatment of PFIC -

ALBO : 30.80 (-2.99%)
Albireo to Present at the William Blair Biotech Focus Conference 2021

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the William...

ALBO : 30.80 (-2.99%)
Albireo to Present at Piper Sandler's Virtual EASL Takeaway Day

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of...

ALBO : 30.80 (-2.99%)
Albireo Announces Expanded Phase 3 Data on Bylvay(TM) (odevixibat) and A3907 at Upcoming EASL International Liver Congress

- Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters -

ALBO : 30.80 (-2.99%)
Albireo to Showcase New Data at the EASL International Liver Congress(TM) 2021

- Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay(TM) (odevixibat) -

ALBO : 30.80 (-2.99%)
New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay(TM) (odevixibat) in PFIC

- Data being presented show long-term benefits of Bylvay in children with PFIC -

ALBO : 30.80 (-2.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States....

See More

Key Turning Points

3rd Resistance Point 33.46
2nd Resistance Point 32.75
1st Resistance Point 31.78
Last Price 30.80
1st Support Level 30.10
2nd Support Level 29.39
3rd Support Level 28.42

See More

52-Week High 49.00
Fibonacci 61.8% 38.98
Fibonacci 50% 35.89
Fibonacci 38.2% 32.80
Last Price 30.80
52-Week Low 22.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar